Trial Profile
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Olipudase alfa (Primary)
- Indications Niemann-Pick disease type B
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Genzyme
- 14 Nov 2023 Results assessing liver and lipid values at baseline and after 2years of olipudase alfa treatment in ongoing clinical trials and extensions (NCT02004691, NCT02292654 NCT02004704, NCT01722526) and phase 1b trial presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 22 Sep 2023 Status changed from active, no longer recruiting to completed.
- 10 Aug 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.